• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ENTX

    Entera Bio Ltd.

    Subscribe to $ENTX
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: enterabio.com

    Peers

    $BXRX
    $PRVB

    Recent Analyst Ratings for Entera Bio Ltd.

    DatePrice TargetRatingAnalyst
    See more ratings

    Entera Bio Ltd. SEC Filings

    See more
    • SEC Form 10-Q filed by Entera Bio Ltd.

      10-Q - Entera Bio Ltd. (0001638097) (Filer)

      5/9/25 4:08:33 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Entera Bio Ltd. (0001638097) (Filer)

      5/9/25 4:05:25 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Entera Bio Ltd.

      SCHEDULE 13G - Entera Bio Ltd. (0001638097) (Subject)

      4/2/25 6:51:11 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Entera Bio Ltd.

      10-K - Entera Bio Ltd. (0001638097) (Filer)

      3/28/25 4:11:12 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Entera Bio Ltd. (0001638097) (Filer)

      3/28/25 4:06:09 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Entera Bio Ltd. (0001638097) (Filer)

      3/17/25 8:00:22 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Ltd. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Entera Bio Ltd. (0001638097) (Filer)

      1/10/25 4:06:21 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Entera Bio Ltd.

      424B5 - Entera Bio Ltd. (0001638097) (Filer)

      1/10/25 4:05:22 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Entera Bio Ltd.

      SCHEDULE 13G - Entera Bio Ltd. (0001638097) (Subject)

      1/6/25 4:10:14 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Entera Bio Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K/A - Entera Bio Ltd. (0001638097) (Filer)

      12/20/24 4:05:26 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Entera Bio Ltd. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Entera Bio with a new price target

      B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00

      6/16/21 6:22:06 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aegis Capital initiated coverage on Entera Bio with a new price target

      Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00

      3/22/21 10:40:44 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group reiterated coverage on Entera Bio with a new price target

      Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously

      3/11/21 12:09:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Entera Bio Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      11/20/24 1:48:55 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      8/20/24 6:01:17 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      1/16/24 10:45:49 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      2/14/23 4:45:47 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      11/18/22 12:40:39 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      11/10/22 5:25:56 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      2/14/22 8:30:13 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Entera Bio Ltd.

      SC 13G - Entera Bio Ltd. (0001638097) (Subject)

      6/30/21 4:33:41 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      6/14/21 12:58:17 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Entera Bio Ltd. (0001638097) (Subject)

      2/16/21 2:48:05 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Entera Bio Ltd. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taitel Haya bought $9,405 worth of Ordinary Shares (9,500 units at $0.99), increasing direct ownership by 37% to 35,115 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/16/24 8:00:12 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taitel Haya bought $5,864 worth of Ordinary Shares (7,615 units at $0.77), increasing direct ownership by 42% to 25,615 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/11/24 6:14:57 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lieberman Gerald M bought $17,006 worth of Ordinary Shares (23,952 units at $0.71), increasing direct ownership by 12% to 226,961 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      12/27/23 5:00:37 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Toledano Miranda Jayne bought $17,006 worth of Ordinary Shares (23,952 units at $0.71), increasing direct ownership by 28% to 110,752 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      12/27/23 8:27:29 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Entera Bio Ltd. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Galitzer Hillel was granted 26,316 units of Ordinary Shares, increasing direct ownership by 41% to 90,573 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      4/30/25 4:22:04 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lieberman Gerald M exercised 23,952 units of Ordinary Shares at a strike of $1.00, increasing direct ownership by 9% to 300,160 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      4/3/25 4:06:27 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Taitel Haya was granted 6,922 units of Ordinary Shares, increasing direct ownership by 12% to 64,650 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/17/25 4:32:49 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Ostrov Gerald M was granted 8,038 units of Ordinary Shares, increasing direct ownership by 21% to 46,936 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/17/25 4:32:17 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Malca Yonatan was granted 8,216 units of Ordinary Shares, increasing direct ownership by 21% to 47,259 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/17/25 4:31:36 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lieberman Gerald M was granted 10,717 units of Ordinary Shares, increasing direct ownership by 4% to 276,208 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/17/25 4:30:58 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Ellis Sean was granted 7,100 units of Ordinary Shares, increasing direct ownership by 6% to 134,727 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/17/25 4:30:09 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Knoll Capital Management, Llc claimed ownership of 5,534,275 units of Ordinary Shares (SEC Form 3)

      3 - Entera Bio Ltd. (0001638097) (Issuer)

      11/20/24 1:53:33 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Taitel Haya was granted 7,278 units of Ordinary Shares, increasing direct ownership by 14% to 57,728 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      10/4/24 4:10:50 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Ostrov Gerald M was granted 8,452 units of Ordinary Shares, increasing direct ownership by 28% to 38,898 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      10/4/24 4:09:10 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Entera Bio Ltd. Financials

    Live finance-specific insights

    See more

    Entera Bio Ltd. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

      JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)

      11/10/22 4:15:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

      Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT  BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o

      5/12/22 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio to Report First Quarter 2022 Financial Results on May 12

      BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a

      4/28/22 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Reports Financial Results for the Year Ended December 31, 2021

      — EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more indications, inventions, patents, and collaborations —— Company to host conference call and webcast today at 8:30 AM EST — BOSTON and JERUSALEM, March 08, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the year ended December 31, 2021, and provided an update on its clinical and pre-clinical programs. 2021 and Recent Highlights Successful End of Phase 2 Meet

      3/8/22 6:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

      BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday, March 8, 2022 at 6:30 AM EST. Entera's management will host a conference call later that morning, Tuesday, March 8, at 8:30 AM EST to discuss the results for the year. A question-and-answer session will follow Entera's remarks. To participate in the live call, please dial (877) 269-7756 (US) or (201) 689-7817 (international) or 1809406247 (Israel) and provide the conference ID "13727633" five to ten minutes befor

      3/3/22 9:50:07 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates

      ‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for Planned Pivotal One-year Phase 3 Study Comparing Changes in Lumbar Spine BMD in Patients Treated with EB613 Versus Treatment with Forteo®, as per a 505(b)(2) Pathway ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. ET ‒ BOSTON and JERUSALEM, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the quarter ended June 30, 2021.

      8/16/21 6:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021

      BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021, on August 16, 2021, at 06:30am ET. Entera's management will host a conference call on Monday, August 16, 2021, at 8:30 a.m. EDT to discuss the results for the quarter. A question-and-answer session will follow Entera's remarks. To participate on the live call, please dial (855) 547-3865 (US) or (409) 217-8787 (international) or 1809457877 (Israel) and provide the conference ID "2056337" five to ten minutes before the start of the call

      8/13/21 4:30:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

      JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman's oral presentation at the 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Congress in Rome entitled "EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY."  EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk

      4/15/25 8:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

      JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.  "2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1-34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balance sheet. To our core team with whom I started this journey in late 2022 as a board member, and to our rapidly expanding ecosystem of premier global advisors, I

      3/28/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

      MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab™ technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo were reported in September 2024. The companies expect to file an In

      3/17/25 8:00:00 AM ET
      $ENTX
      $OPK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entera Bio to Participate in Upcoming Events

      JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences.  Leerink Partners Global Healthcare ConferenceMarch 12, 2025, in person 1x1 meetings, Location: Miami, FL 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO)Oral Presentation:  Friday April 11 at 10:00 GMT, Roma Convention Center, Auditorium APoster Presentation: April 13, 2025 8:30-13:00 Poster # P1265 2025 BIO International ConventionJune 16-19, 2025

      2/24/25 8:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

      JERUSALEM , Feb. 19, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Scientific Programme Committee has accepted both submitted abstracts related to EB613 for presentation at the WCO-IOF-ESCEO congress. The congress will take place at the Roma Convention Center, Rome, Italy from April 10 to April 13, 2025. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic 

      2/19/25 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

      JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11 – 12, 2025 in a virtual format. The presentation scheduled for Tuesday, February 11th at 12:40-1:10 PM ET in Track 1 will feature a business overview and update by Miranda Toledano, the Company's Chief Executive Officer. About Entera Bio Entera is a clinical-stage company focused on developing tablet treatments of peptide and small protein re

      1/27/25 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

      JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. "The third quarter of 2024 drew consistent attention to our pivotal-staged clinical asset, EB613, the first oral PTH(1-34) tablet treatment dedicated to post-menopausal women with high risk osteoporosis. Entera's proprietary N-Tab™ platform consistently delivered across our oral GLP-2 tablet, oral GLP-1/Glucagon tablet and confidential hypoparathyroidism tablet program. Finally, we are humbled by key additions

      11/8/24 4:05:00 PM ET
      $ENTX
      $OPK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

      JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ:OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that

      9/25/24 8:30:00 AM ET
      $ENTX
      $OPK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entera Bio to Participate in Upcoming Investor and Scientific Conferences

      JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences: H.C. Wainwright 26th Annual Global Investment Conference (Presentation and 1x1) Date and Time: September 9, 2024 at 7am ETLocation: Virtual, September 9-11, 2024 American Society for Bone and Mineral Research 2024 Annual Meeting (Poster and 1x1) Date and Time: Saturday, September 28, 2024, 2:15 – 3:45PM Location: In person, September 26-29, 2024 Toronto, Canada 7th Annual Evercore ISI Heal

      8/20/24 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Entera Bio Ltd. Leadership Updates

    Live Leadership Updates

    See more
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

      JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

      5/15/24 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

      JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd

      6/7/23 7:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

      JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro

      7/18/22 7:05:00 AM ET
      $CMPX
      $DERM
      $ENTX
      $NXGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

      BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's

      5/16/22 8:00:00 AM ET
      $CMPX
      $DERM
      $ENTX
      $NXGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Entera Appoints Ramesh Ratan as Chief Financial Officer

      BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who was serving as Entera's interim U.S. CFO. Mr. Ratan brings 40 years of experience at biomedical, tech, and Fortune 500 companies in senior, executive, vice president, and C-level positions. He was most recently CFO, Head of Manufacturing, and Corporate Secretary at AOBiome. He served as CFO at Xcellerex, Enanta Pharmaceuticals, Repligen, and held positions at

      4/15/21 8:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Issues Letter to Shareholders

      BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors. Dear Shareholders, We hope you and your family have fared well and been healthy during a difficult 2020. As we begin the new year, we are hopeful the global community, with a little help from the biopharmaceutical industry, will overcome the most significant pandemic in a century. Personally, I am thrilled to start 2021 leading Entera and its highly promising oral protein drug deli

      1/11/21 8:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care